Catalyst
Slingshot members are tracking this event:
Bausch + Lomb (BHC) expecting FDA decision on Loteprednol Gel 0.38% for Ocular Inflammation, PDUFA date February 25, 2019
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| BHC | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 25, 2019
Occurred Source:
https://www.bauschhealth.com/news-room/news-releases/news-details/201902250700pr_news_uspr_____ny63444
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Loteprednol, Ocular Inflammation
